Clinical Trial Update: 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating 3-AP (Triapine) in combination with Gemcitabine as second-line therapy for stage III or IV recurrent non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Triapine (3-AP) (3-aminopyridine-2-one)

Snippet

Sponsor: Cancer Therapeutics Research Group | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED